Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model.

Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapeutics, Center for Biologics Evaluation and Research, Food and Drug Administration, NIH Bldg 29B/2E08, Bethesda, MD 20892, USA.
Blood (Impact Factor: 9.78). 06/2005; 105(9):3707-13. DOI: 10.1182/blood-2004-08-3216
Source: PubMed

ABSTRACT Hodgkin lymphoma represents unique clinicopathologic features because Hodgkin and Reed-Sternberg (H-RS) cells produce a variety of cytokines, express a variety of cytokine receptors, and are surrounded by numerous nonmalignant immunoreactive cells. We found that receptors for interleukin-4 (IL-4R) are highly expressed in H-RS cells. To target interleukin-4 receptor (IL-4R), we used a recombinant protein fusing circularly permuted human IL-4 and Pseudomonas exotoxin termed IL4(38-37)-PE38KDEL, or IL-4 cytotoxin. The cytotoxic effect of IL-4 cytotoxin on H-RS cell lines was determined to be moderate to high in vitro. We developed an infiltrating model of Hodgkin disease (HD) by injecting an adherent population of HD-MyZ cells subcutaneously into the flanks of beige/nude/X-linked immunodeficient mice. The animal model exhibited spontaneous metastasis of H-RS cells to lymph nodes and dissemination to vital organs, including the lungs. Intraperitoneal or intratumoral treatment of these mice with IL-4 cytotoxin resulted in regression of the primary tumor mass and a decrease in the incidence of lymph node metastasis. Mice injected with HD-MyZ cells demonstrated 203% prolonged survival (mean survival, 63 days) compared with control (mean survival, 31 days) when they received systemic IL-4 cytotoxin treatment. Because numerous H-RS cell lines express receptors for IL-4, IL-4 cytotoxin may be a unique agent for the treatment of Hodgkin lymphoma.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Hodgkin/Reed-Sternberg lymphoma (HL) is a clonal B-cell-related malignancy. Although many patients with HL can be cured by the current regimen of high-dose multi-agent chemotherapy, the treatment causes high risks of later pathologies including secondary malignancies. This fact highlights the demand to develop rational treatment for HL. Survival and growth of HL cells are largely dependent on their microenvironment. In this study, using the HL cell lines L1236 and KM-H2 as model systems, we investigated the role of IL-4/IL-13 signaling in regulation of drug sensitivity and resistance in HL. We show that specific blocking of IL-4 and IL-13-mediated STAT6 activation by either an IL-4-binding fusion protein APG598 or an IL-4R antagonist APG201 (R121D/Y124D) renders HL cells more prone to apoptotic killing by chemotherapeutic drugs such as Mitomycin C, 5-Fluorouracil and Paclitaxel. This effect is due to inhibition of STAT6-mediated elevation of expression of the anti-apoptotic Bcl-2 family protein Bcl-xL. Employing ChIP analysis in combination with APG201 or STAT6-specific siRNA we identified a defined STAT6-binding site in the Bcl-xL promoter region from -1967 to -1957 of the transcription start site. Our data demonstrate that the IL-4/IL-13-STAT6-Bcl-xL axis may be an important target for HL treatment. This study also suggests that combination of classical chemotherapeutic drugs with the IL-4/IL-13 antagonists may enhance efficacy and reduce risks of toxicity from high dose of drugs in HL treatment. © 2013 Wiley Periodicals, Inc.
    International Journal of Cancer 10/2013; 133(8). DOI:10.1002/ijc.28189 · 5.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Summary Classical Hodgkin lymphoma is a lymphoid neoplasm consisting of mononuclear Hodgkin and multinuclear Reed-Sternberg cells, mostly of B-cell origin, embedded in a non-neoplastic background. Most patients are cured with the current risk- and response adapted therapy, albeit a portion of patients either will fail to respond or will relapse. An important drawback, considering the healed individuals, is the increasing late toxicity, particularly the high incidence of secondary malignancies. Landmark discoveries from the recent decade point towards the significance of a few molecular pathways in classical Hodgkin lymphoma pathogenesis, to which Hodgkin and Reed-Sternberg cells are oncogenically addicted. Several players of these oncogenic pathways can be or are now targeted in in vitro and in vivo models as well as in early clinical trials. Some of these oncogenic pathways in Hodgkin and Reed-Sternberg cells that could form the basis for rational molecular modulations as well as current data from targeted-therapy studies aiming at these pathways will be summarized in the review.
    memo - Magazine of European Medical Oncology 09/2008; 1(3):161-165. DOI:10.1007/s12254-008-0054-x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Graphical abstract Figure optionsDownload full-size imageDownload as PowerPoint slide
    Iranian Journal of Medical Hypotheses and Ideas 05/2014; DOI:10.1016/j.jmhi.2014.05.002

Full-text (2 Sources)

Available from
May 22, 2014